Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rankning i aktier #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aktiekurs
$0.01292666
Senast synkroniserad: 2025-04-08
Marknadsvärde
$157.54K
Förändring (1 dag)
6.84%
Förändring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

Utdelningsavkastning för Synairgen plc (SNG)
Utdelningsavkastningen (TTM) för Synairgen plc (aktiesymbol: SNG) per 2022-12-31 är: 0.00%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Synairgen plc (SNG) från 2004 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter